Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
about
Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end pointsCardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trialSurgical resection combined with chemotherapy can help achieve better outcomes in patients with primary colonic lymphoma.Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics.A randomized trial comparing intensified CNOP vs. CHOP in patients with aggressive non-Hodgkin's lymphoma.
P2860
Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
@en
Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
@nl
type
label
Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
@en
Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
@nl
prefLabel
Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
@en
Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
@nl
P2093
P2860
P1476
Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
@en
P2093
Economopoulos T
Nicolaides C
Papadopoulos A
Papageogriou E
Papasavvas P
Pavlidis N
Samantas E
Tsatalas C
P2860
P304
P356
10.1034/J.1600-0609.2002.01620.X
P577
2002-03-01T00:00:00Z